Author pages are created from data sourced from our academic publisher partnerships and public sources.
Conditional PTEN-deficient mice as a prostate cancer chemoprevention model.
BACKGROUND We generated a mouse model of prostate cancer based on the adult-prostate-specific inactivation of phosphatase and tensin homolog (PTEN) using the Cre-loxP system. The potential of our… Expand
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
- Y. Yamamoto, M. D. de Velasco, +10 authors H. Uemura
- Journal of Translational Medicine
- 8 May 2015
BackgroundDespite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the… Expand
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
- M. D. de Velasco, Yurie Kura, K. Yoshikawa, K. Nishio, B. Davies, H. Uemura
- 21 February 2016
The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to… Expand
Generation of PTEN‑knockout (‑/‑) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
Phosphatase and tensin homolog (PTEN) deficiency is associated with development, progression, and metastasis of various cancers. However, changes in gene expression associated with PTEN deficiency… Expand
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
Sustained therapeutic responses from traditional and next-generation antiandrogen therapies remain elusive in clinical practice due to inherent and/or acquired resistance resulting in persistent… Expand
Abstract 4702: PD-L1 blockade in preclinical models ofPTEN-deficient prostate cancer
Immune checkpoint blockade with antibodies aimed at enhancing antitumor immunity have become an attractive therapeutic option. Establishing immunocompetent and clinically relevant models that predict… Expand
Abstract 3629: HOXA10 expression profiles in prostate cancer
HOXA10 is a member of the homeobox gene family and is a transcription factor primarily involved in embryonic development. Perturbed HOX gene expression has been identified in numerous cancers and… Expand
Abstract 1857: Effects of long-term chloroquine chemotherapy in a preclinical model of PTEN-deficient prostate cancer
Abstract 4699: Preclinical activity of the AKT inhibitor AZD5363 in PTEN-deficient mouse models of prostate cancer
Increased phosphoinositide 3-kinase (PI3K) pathway activity is commonly observed in human prostate cancer and constitutes a potential target for therapeutic intervention. AZD5363 is a potent pan-AKT… Expand
Abstract 1226: Interleukin-6 (IL-6) as a therapeutic target in prostate cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Interleukin-6 or IL-6 is a pleiotropic cytokine which is implicated in the regulation of immune response, but is also… Expand